DK1315519T3 - Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til behandling af cancer eller leverfibrose - Google Patents

Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til behandling af cancer eller leverfibrose

Info

Publication number
DK1315519T3
DK1315519T3 DK01958338.4T DK01958338T DK1315519T3 DK 1315519 T3 DK1315519 T3 DK 1315519T3 DK 01958338 T DK01958338 T DK 01958338T DK 1315519 T3 DK1315519 T3 DK 1315519T3
Authority
DK
Denmark
Prior art keywords
methods
pharmaceutical compositions
liver fibrosis
treat cancer
mammalian tissue
Prior art date
Application number
DK01958338.4T
Other languages
English (en)
Inventor
Stela Gengrovitch
Gera Neufeld
Gal Akiri
Zahava Vadasz
Original Assignee
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Res & Dev Foundation filed Critical Technion Res & Dev Foundation
Application granted granted Critical
Publication of DK1315519T3 publication Critical patent/DK1315519T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03013—Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01958338.4T 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til behandling af cancer eller leverfibrose DK1315519T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22373900P 2000-08-08 2000-08-08
PCT/IL2001/000728 WO2002011667A2 (en) 2000-08-08 2001-08-07 Pharmaceutical compositions and methods useful for modulating angiogenesis

Publications (1)

Publication Number Publication Date
DK1315519T3 true DK1315519T3 (da) 2011-04-11

Family

ID=22837793

Family Applications (4)

Application Number Title Priority Date Filing Date
DK10012457.7T DK2359853T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese
DK10012458.5T DK2359854T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder egnet til modulering af angiogenese
DK08020754.1T DK2078531T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til modulering af angiogenese
DK01958338.4T DK1315519T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til behandling af cancer eller leverfibrose

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK10012457.7T DK2359853T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese
DK10012458.5T DK2359854T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder egnet til modulering af angiogenese
DK08020754.1T DK2078531T3 (da) 2000-08-08 2001-08-07 Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til modulering af angiogenese

Country Status (9)

Country Link
EP (4) EP2359854B1 (da)
AT (1) ATE493147T1 (da)
AU (1) AU2001280056A1 (da)
CY (3) CY1111869T1 (da)
DE (1) DE60143754D1 (da)
DK (4) DK2359853T3 (da)
ES (4) ES2440932T3 (da)
PT (4) PT1315519E (da)
WO (1) WO2002011667A2 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030224989A1 (en) * 2002-02-12 2003-12-04 Kerry Quinn Compositions and methods for treatment of osteoarthritis
FR2855968B1 (fr) * 2003-06-13 2012-11-30 Coletica Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
WO2005069975A2 (en) 2004-01-23 2005-08-04 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (loxl1) and elastogenesis
WO2006128740A2 (en) * 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
DE102007051006A1 (de) * 2007-10-25 2009-04-30 Lanxess Deutschland Gmbh Stabile, synergistische Mischungen
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
SG178845A1 (en) 2009-08-21 2012-04-27 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
WO2001083702A2 (en) * 2000-05-03 2001-11-08 University Of Hawaii Novel members of the lysyl oxidases family of amine oxidases related applications
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis

Also Published As

Publication number Publication date
EP2359853A1 (en) 2011-08-24
HK1131912A1 (en) 2010-02-12
EP2078531A3 (en) 2010-01-20
DK2359854T3 (da) 2013-11-04
CY1113142T1 (el) 2016-04-13
DE60143754D1 (de) 2011-02-10
PT2078531E (pt) 2012-08-06
PT1315519E (pt) 2011-03-17
WO2002011667A3 (en) 2003-03-27
PT2359854E (pt) 2013-11-22
EP2078531B1 (en) 2012-05-30
DK2078531T3 (da) 2012-09-10
EP2359854A1 (en) 2011-08-24
ES2387329T3 (es) 2012-09-20
AU2001280056A1 (en) 2002-02-18
EP2078531A2 (en) 2009-07-15
DK2359853T3 (da) 2013-12-09
WO2002011667A2 (en) 2002-02-14
EP1315519B1 (en) 2010-12-29
PT2359853E (pt) 2013-12-26
ES2437093T3 (es) 2014-01-08
ES2358581T3 (es) 2011-05-12
EP2359853B1 (en) 2013-11-06
EP1315519A2 (en) 2003-06-04
EP2359854B1 (en) 2013-10-09
HK1161115A1 (en) 2012-08-24
CY1114734T1 (el) 2016-12-14
ES2440932T3 (es) 2014-01-31
HK1161113A1 (en) 2012-08-24
CY1111869T1 (el) 2015-11-04
EP1315519A4 (en) 2005-09-14
ATE493147T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
CY1113142T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι χρησιμοι για τη διαμορφωση της αγγειογενεσης
DK1206261T3 (da) Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
FI952337A0 (fi) Juoksevaan muotoon saatettu suolen limakalvonalaiskudos ja sen käyttö injektoitavissa olevana kudossiirteenä
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
EP1024827A4 (en) COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF ORAL VACCINES AND THERAPEUTICS
DK0413528T3 (da) Amphotere præparater og polymere former af alphahydroxysyrer og deres terapeutiske anvendelse
AR044146A1 (es) Uso de una toxina botulinica para preparar una composicion farmaceutica de utilidad en un metodo para tratar la cefalea sinusal
NO923948D0 (no) Tiofensulfonamider som kan anvendes som karbonsyre-anhydraseinhibitorer
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69133022D1 (de) Viral verursachte Zerstörung von Neoplastzellen
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
SE0201713D0 (sv) New methods and use III
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
ATE75395T1 (de) Linolensaeuren enthaltende pharmazeutische und diaet-zusammensetzungen zur behandlung von gutartiger prostatahypertrophie.
EP1268507A4 (en) ANTISENSE MODULATION OF E2F-1 TRANSCRIPTION FACTOR
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DE59604491D1 (de) Polymerisierbare aromatische carbonsäuren und carbonsäureanhydride mit cyclischen carbonatgruppen sowie zubereitungen, enthaltend diese verbindungen
DK0797997T3 (da) Anvendelse af peptidiske bradykinin-antagonister til fremstilling af lægemidler
DE60044539D1 (de) Impfstoff enthaltend lactobacilli zur behandlung von entzündungen der prostata und gutartigen prostata-hyperplasien
ATA17782002A (de) Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
DK1092427T3 (da) Anvendelse af et peptid, der forebygger hudintolerancereaktioner, især i kosmetiske præparater
DE50006409D1 (de) Injektionslösung enthaltend eine goldverbindung, calendula und belladonna extrakte zur behandlung von arthrosen